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Abstract. Implantation is the final and most important stage of 
embryogenesis and is of paramount importance in achieving a 
successful pregnancy. Progesterone and estrogen are steroid 
hormones responsible for the regulation of the implantation 
window and the current study hypothesised that their recep-
tors may be implicated in women undergoing oocyte donation. 
A total of 15 women aged 25‑32 years old (mean ± SD, 
28.9±2.89) undergoing oocyte donation were recruited into 
the present study. Participants underwent ovarian stimulation 
with gonadotrophin‑releasing hormone antagonist and recom-
binant follicle‑stimulating hormone. Endometrial aspiration 
biopsy was performed on the day of oocyte retrieval and after 
5 days (on days 0 and 5, respectively). Endometrial histology 
and evaluation of estrogen receptor (ER)α and progesterone 
receptor (PR)‑B were performed on days 0 and 5. The ER 
nodal staining percentage on day 0 was age‑associated, with 
patients aged <30 years demonstrating 100% staining and 
those aged >30 years exhibiting 90% staining. Pathological 
staining revealed statistically significant differences between 
days 0 and 5 following all staining procedures. Wilcoxon 
signed‑rank test resulted in the following P‑values, for ER 
(nodes % and stromal %) day 0/5, P=0.0001; for PR (nodes % 
and stromal %) day 0/5, P=0.0001 and P=0.035, respectively; 
for ER (grade nodes and stromal %) day 0/5, P=0.0001; and PR 
(grade nodes and stromal %) day 0/5 P=0.0001 and P=0.016, 
respectively. Synchronization between blastocyst development 
and the acquisition of endometrial receptivity is a prerequisite 
for the success of in vitro fertilisation (IVF). Aside from the 
recent discovery of molecules that are considered crucial 
for successful embryo implantation, assessing the functional 
characteristics of the endometrium may offer unique insights 
into this process, thus improving IVF results.
Introduction
Implantation is defined as the organized process through which 
the blastocyst attaches to the endometrium and invades the 
epithelium to form the placenta. Implantation is directly depen-
dent on the synchronization of the fertilized egg's progression 
into a blastocyst and the specific differentiation of the endo-
metrium through molecular and cellular changes regulated by 
agents with an endocrine, paracrine or autocrine activity (1,2). 
This synchronization occurs over a certain period of time, 
called the ‘window of implantation’, and requires a molecular 
dialogue of sorts between the secretory activity of the endome-
trium and that of the blastocyst (1‑3). Numerous studies have 
implicated adhesion molecules, extracellular matrix proteins, 
growth factors, extracellular substrate degradation proteins 
and pro‑inflammatory agents in the implantation process of 
the blastocyst into the endometrium (4). Collectively these data 
point towards a complex molecular process, whose underlying 
mechanisms have not been fully elucidated.
Progesterone and estrogen are the steroid hormones 
responsible for the regulation of the implantation window. 
Progesterone induces changes in signalling pathways that lead 
to the establishment of a receptive endometrium (5). Estrogen 
receptors (ER)α and β and progesterone receptors (PR)‑A and 
‑B are expressed in the epithelium and stroma of the human 
endometrium. ER mediates most of the biological effect of 
estrogens by interacting with its site‑specific DNA and with 
other coregulatory proteins, while ER and PR signalling during 
implantation is carried out through paracrine and autocrine 
factors mediated by growth factors, as well as cytokines (6). 
Progesterone exerts its effects by activating the canonical PRs to 
act in a genomic fashion to regulate transcriptional responses of 
implantation‑related genes (5). For example, progesterone drives 
an increase in the gene expression of integrin αvβ3 in epithelial 
cells (7). Integrins are a family of transmembrane binding glyco-
proteins consisting of two protein subunits (α and β). Integrins 
function as receptors for extracellular matrix molecules, glyco-
proteins and other cells, and their concentration in adhesion 
points leads to the creation of a network of cytoskeletal proteins 
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and intracellular signalling (8,9). The importance of these adhe-
sion molecules has been widely studied in mice with blastocysts 
lacking the β1 subunit that fail to implant (10,11).
Other adhesion molecules also play a crucial role in this 
dialogue underlying the adhesion and attachment of the blasto-
cyst in the adequately prepared endometrium (12). E‑cadherin, 
for example, is critical to the creation and maintenance of 
blastocyst adhesion ligands (12‑14). Since E‑cadherin has 
been found in the trophoblast and endometrium, it has been 
suggested to participate in the initial adhesion and attachment 
of the blastocyst during implantation (15).
On the other hand, estrogens exert their effects by activating 
primarily the nuclear steroid hormone receptor. ERα appears to 
be upregulated during the proliferative phase and down regulated 
during the implantation window, an event driven primarily 
by progesterone (16). Of note, elevated levels of ERα during 
implantation were associated with a decrease in β3 integrin 
expression in patients with polycystic ovarian syndrome and 
endometriosis (17). It has been suggested that the disappearance 
of ERα at the time of implantation may disturb the expression 
pattern of proteins that regulate endometrial receptivity.
Despite the existence of a plethora of studies on the role of 
these steroid hormones and their receptors at the endometrial 
level, knowledge around their protein expression and tissue 
distribution during the implantation window (days 0‑5) in 
humans remains limited. One of the main reasons for this lack 
of knowledge is that participants in such studies are required 
to undergo endometrial biopsy, which obviously affects endo-
metrial receptivity and subsequently the success of in vitro 
fertilisation (IVF). Therefore, it is not feasible to carry out 
a study in women undergoing IVF, since the procedure will 
have an adverse effect on the outcome. The patient population 
of the present study consisted of women undergoing ovarian 
stimulation for egg donation.
In this study the following question was addressed: Can 
morphological and functional markers be used to evaluate the 
changes in the endometrium during implantation in women 
undergoing IVF?
In this study we investigated whether morphological and 
functional markers (i.e. ER and PR) can be used to evaluate the 
changes in the endometrium during implantation in women 
undergoing IVF.
Materials and methods
Study population and design. The study was conducted at the 
1st Dept. of OB‑GYN, Centre for Human Reproduction of the 
Aristotle University of Thessaloniki, ‘Papageorgiou’ General 
Hospital and the ‘Biogenesis’ Assisted Reproduction Centre, 
(both in Thessaloniki, Greece). The participants recruited for 
this prospective study included 15 oocyte donors (age range, 
25‑32 years; mean age, 28.9±2.89) undergoing IVF treatment. 
The inclusion criteria were white race, no uterine‑ovarian 
pathology, age <35 years and no prior known medical pathology. 
All donors had undergone extensive preoperative work‑up, 
which included common blood tests, karyotyping, specific test 
for cystic fibrosis and pap smear. All donors were non‑smokers 
and had given their informed consent (NP: Α 13032 15/7/10). 
Informed consent was written, and patients agreed to the use 
of their samples in scientific research.
Participants underwent ovarian stimulation with gonad-
otrophin‑releasing hormone antagonist and recombinant 
follicle‑stimulating hormone (18‑20). Endometrial aspiration 
biopsy was performed using a Z‑Sampler (Gynétics) on the 
day of oocyte retrieval and 5 days later (Fig. 1A).
Immunohistochemistry. Endometrial histology was evalu-
ated blindly, using the Noyes criteria by a single specialized 
pathologist (20). The tissue was fixed in neutral buffered 
formalin 10% and followed the usual technical procedure 
for histological samples and embedding in paraffin blocks. 
Sections (3 µm thickness) were sliced from the blocks placed 
on slides and then stained with hematoxylin and eosin for the 
evaluation of histologic characteristic. Immunohistochemistry 
was used to evaluate expression of ERα and PR‑B, using 
monoclonal antibodies (ER: Clone 4f11, PR:clone 16+SAN27; 
Leica). Immunohistochemistry was performed on Ventana 
Benchmark XT automatic immunostainer (Ventana Medical 
Systems Inc.) using OptiView DAB IHC detection kit (Roche) 
as a detection method. As part of the automated service 
positive and negative controls (immunoglobulin G control) 
were tested simultaneously with the test slides (Fig. S1). The 
percentage of epithelial cell nuclei positive for ERα and PR‑B 
receptors was recorded on days 0 and 5. Slide photos were 
captured using a x10‑magnification lens on a Leica DMi1 
Inverted Microscope (Leica Microsystems, Inc.), with all 
scale bars set to 0.25 mm.
Bioinformatic analysis. GeneMANIA (http://genemania.
org/), a user‑friendly web interface that provides large datasets 
to perform analyses for gene and protein interactions and 
prioritise genes for functional assays. Using this software, the 
relationship between ER and PR with 43 previously identified 
genes (21) involved with unexplained infertility (UIF) and 
recurrent implantation failure (RIF) were used to generate PPI 
networks using GeneMANIA.
Statistical analysis. Statistical analysis was performed using 
the SPSS version 23 (IBM Corp.). The data were non‑para-
metric (Shapiro‑Wilk normality test P<0.005), and as such, 
the Wilcoxon signed‑rank, Mann‑Whitney U and Fisher's 
exact tests were used for analysis. A two‑tailed P<0.05 was 
considered to indicate a statistically significant difference. 
Sample stratification (for ER staining only) was performed 
for ages (±30 years old) and to determine whether there was 
differential gene expression between the two days (yes, no).
Results
Differential expression of steroid hormone receptors during 
the implantation window. Both ERα and PR‑B were expressed 
abundantly on both days (0 and 5; Fig. 1B). The ERα nodal 
staining percentage on day 0 was age‑related, with patients aged 
<30 years showing 100% staining and those aged >30 years 
showing 90% staining (Mann‑Whitney U test; P=0.014; Fig. 2A).
Both steroid hormone receptors showed significant 
variation between days 0 and 5, both in the nodal and stromal 
preparations. According to Wilcoxon signed‑rank test; for ER 
(nodes % and stromal %) Day 0/5, P=0.0001; for PR (nodes % 
and stromal %) Day 0/5, P=0.0001 and P=0.035, respectively; 
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for ER (Grade nodes and stromal) Day 0/5, P=0.0001; and for 
PR (Grade nodes and stromal) Day 0/5, P=0.0001 and P=0.016, 
respectively (Fig. 2B and C; Table I).
Involvement of ER and PR‑B in endometrial gene networks: 
An in‑silico analysis. In a recent meritorious study, microarray 
datasets collected during the time of human uterine receptivity 
and implantation were compared to the transcriptome signa-
ture of women with unexplained infertility (UIF) and recurrent 
implantation failure (RIF) (21). In that study, the authors have 
identified 24 and 21 shared differentially expressed genes 
(DEGs) between the transcriptome of women with UIF and 
RIF and those of normal endometrial receptivity samples 
(Table II) (21).
In view of the differential expression of ER and PR‑B during 
the implantation window, their potential involvement was 
investigated further by studying potential interactions between 
the common genes for UIF and RIF using GeneMANIA 
software. The previously identified UIF genes (21) that poten-
tially interact with ER are as follows: Thyrotropin releasing 
hormone (TRH), TRH receptor (TRHR), GLI family zinc 
finger 1, matrix metallopeptidase 26 (MMP26), retinol binding 
protein 4, serpin family A member 1, MMP7, catenin α 2, hyal-
uronan binding protein 2, collagen type IX α 1 (Fig. 3A). PR‑B 
appears to interact with the following genes: Chromosome 20 
open reading frame 103, calpain 6, thrombospondin 4, leucine 
rich repeat containing 17, periostin, collagen type IV α 6 chain, 
TRH, TRHR, nidogen 2, MMP7, MMP26, oviductal glyco-
protein 1 (OVGP1), Jun dimerization protein 2, endothelin 
converting enzyme like 1, insulin like growth factor binding 
protein 1 (IGFBP1), Kruppel‑like factor 9 (Fig. 3B).
In the case of previously identified RIF overlapping 
genes (21), potential interactions with ER include: Prostaglandin 
E receptor 3, Wilms tumor 1 (WT1), progestogen‑associated 
endometrial protein (PAEP), odd‑skipped related transcrip-
tion factor 2, progesterone receptor, nidogen 1, nuclear factor 
I/A, splicing factor 1 (SF1; Fig. 4A). PR‑B interacts with the 
following genes: Clusterin, solute carrier family 9 member A3, 
OVGP1, PAEP, superoxide dismutase 3, extracellular, ribo-
nucleotide reductase regulatory TP53 inducible subunit M2B, 
ephrin B2, hydroxysteroid 17‑β dehydrogenase 2 (HSD17B2), 
kallikrein related peptidase 3, and IGFBP1 (Fig. 4B).
Discussion
Successful implantation following IVF is a complex procedure 
that is very much dependent on the fertilized egg's progres-
sion into a blastocyst, synchronized with the differentiation 
of the endometrium (1,2). This ‘implantation window’ initi-
ates a molecular dialogue of sorts that has not yet been fully 
clarified (1‑4).
The aim of the present study was to elucidate a small 
part of this dialogue. These results, in combination with the 
Figure 1. Biopsy removal and immunohistochemistry for ERα and PR‑B. 
(A) Schematic diagram of the biopsy procedure. (B) Examples of immu-
nohistochemistry for ERα and PR‑B. Scale bar, 0.25 mm. ERα, estrogen 
receptor α; PR‑B, progesterone receptor‑B; D, day; GnRH, gonadotropin 
releasing hormone.
Figure 2. Differences in the expression grade and location of ERα and PR‑B. 
(A) Frequency of ER expression stratified by age. ERα and PR‑B expres-
sion on days 0 and 5. Pie charts of histopathology results for positive nuclei 
percentage and receptor grade per location for both (B) ERα and (C) PR‑B. 
ERα, estrogen receptor; PR‑B, progesterone receptor‑B; D, day.
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number of ERs and PRs, play an important role in the success 
of IVF, since their expression causes a series of paracrine and 
autocrine signals, which through adhesion molecule processes 
ultimately lead to the successful adhesion and penetration of 
the endometrium by blastocysts (22). As far as permeability 
is concerned, the effect of ovarian steroids on the uterus is 
achieved through their receptors (23). Immunohistochemistry 
results for ER receptors showed a significant reduction in D5, 
as compared to D0, while an equally significant increase in the 
PR receptors was observed on the same days. Nodal ER and PR 
receptors with a strong presence on day 0 showed a very limited 
presence on day 5, while only PR receptors were strongly 
represented in the stroma. Estrogens in the follicular phase 
prepare the endometrium for the action of progesterone in the 
subsequent secretory phase of the cycle (24). Having stratified 
our samples into two age‑groups (<30 and >30 years), it was 
found that the ER receptor nodal staining percentage on day 0 
was age‑related, with patients aged <30 years showing 100% 
staining and those aged >30 years showing 90% staining. This 
was consistent with potential age‑related complications asso-
ciated with maternity and successful pregnancy. Progesterone 
is another determining factor in the creation of the implanta-
tion window and the maintenance of pregnancy. The stromal 
cells differentiate into progesterone‑responsive peristaltic 
cells during the perforation process, which is characterized by 
morphological changes (25). In the present study, changes in 
the expression of PR‑B were observed between days 0 and 5. 
This was consistent with a study showing that stimulation of 
the endometrium with ganirelix acetate (a GnRH antagonist) 
and gonadotropins led to the increase of PR‑B gene expression 
at the time of embryo transfer (26). Of note, in the same study 
it was only the expression of PR‑B that changed, while PR‑A, 
the other splice isoform of the PR, was undetectable. It should 
be noted that, in addition to the two well studied variants of 
PR‑A and ‑B, other splicing isoforms have also been detected 
including PR‑C and PR‑M (27). Moreover, it is now well 
accepted that both steroids can activate membrane‑bound 
receptors acting in a non‑genomic manner (28,29). Future 
studies should also concentrate on elucidating the expression 
of these receptors during the implantation window. Finally, 
evidence of a potential crosstalk between these receptors and 
genes implicated in RIF and UIF during the implantation 
window was provided herein, using data previously gener-
ated (21). This is of interest, given that these genes are involved 
in key physiological processes, such as the regulation of the 
protein activation cascade, complement activation, humoral 
immune response, acute inflammatory response or protein 
processing in the case of the gene cluster, which is common 
in RIF. One of the most interesting interactions of both ER 
and PR is with TRH and TRHR in UIF. Previous studies 
have corroborated these in silico findings in other in vitro or 
in vivo systems. For example, 17β‑estradiol (E2) was found to 
modulate the prolactin secretion induced by TRH in a female 
anterior pituitary primary cell culture. This response was medi-
ated by a membrane‑ER, but this finding provided an insight 
into a potential crosstalk (30). Similarly, E2 appears to inhibit 
TRH expression in the hypothalamic paraventricular nucleus 
of female rats (31). Similarly, TRHR immunoreactivity in the 
myometrium of cynomolgus macaques was increased when 
they were treated with conjugated equine estrogens alone or in 
Table I. Descriptive statistics of immunohistochemical analysis.
Parameter N Minimum Maximum Mean SDEV
Age (years) 15 25 32 28.93 2.89
A, Day 0     
  ER nodal grade 15 2.00 3.00 2.87 0.35
  ER stromal grade 15 2.00 2.00 2.00 0.00
  ER nodal % 15 0.90 1.00 0.95 0.05
  ER stromal % 15 0.70 0.90 0.80 0.08
  PR  nodal grade 15 2.00 3.00 2.73 0.05
  PR stromal grade 15 2.00 3.00 2.87 0.35
  PR nodal % 15 0.90 1.00 0.93 0.05
  PR stromal % 15 0.80 1.00 0.95 0.07
B, Day 5     
  ER nodal grade 15 1.00 1.00 1.00 0.00
  ER stromal grade 15 1.00 2.00 1.07 0.26
  ER nodal % 15 0.15 0.30 0.24 0.05
  ER stromal % 15 0.15 1.00 0.24 0.21
  PR  nodal grade 15 1.00 1.00 1.00 0.00
  PR stromal grade 15 2.00 3.00 2.40 0.51
  PR nodal % 15 0.15 0.25 0.18 0.03
  PR stromal % 15 0.70 1.00 0.89 0.06
ER, estrogen receptor; PR, progesterone receptor; SDEV, mean ± SD.
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combination with medroxyprogesterone acetate (32). Another 
common pathway that estrogen and progesterone appear 
to modulate is that of MMP7. Again, previous studies have 
corroborated this interaction. There has been an association 
between cellular and molecular responses in the rat mammary 
gland and E2, including MMP7 and MMP9 (33). When female 
sheep pups were treated with P4, it led to a reduced expression 
of MMP7. Moreover, P4 inhibited uterine gland development 
in the uterus of a neonatal mouse; a process that involved 
the downregulation of MMP7 (34). Endometriotic cells have 
been found to contain the full complement of steroidogenic 
genes such as SF1 and WT‑1, which can influence the tran-
scription of steroidogenic genes necessary for E2 synthesis in 
endometriosis (35). A similar interplay between ER‑SF1‑WT1 
was produced as interactions under RIF conditions. On the 
other hand, P4 inhibited the stimulatory effect of E2 on the 
expression of oviductin in the cervix of rhesus macaques (36). 
In addition, HSD17B2 expression in endometrial epithelial 
cells was found to be regulated by downstream molecules of 
progesterone (37).
Finally, we have shown using qRT‑PCR that patients that 
were E‑Cadherin‑positive between days 0 and 5 were also all 
PR Grade 3. The small sample of this study clearly limits its 
scientific value, particularly with regards to very low gene 
expression, and lack of any statistical strength. We appreciate 
that this is a limitation of the current study. However, it should 
be noted that endometrial sampling at Day 5 is considered 
an invasive procedure and a cause of some discomfort to the 
individual, so it is very hard to recruit large numbers. Despite 
close follow‑ups of the oocyte recipients, matching the 
morphological‑structural changes of the donor endometria and 
the IVF result was not feasible, due to the anonymous nature 
of the oocyte donation procedure. It should be noted that the 
present the present study is limited to young women (due to 
better quality of oocytes and lower incidence of trisomy 21) 
and future studies should aim to test whether the present 
findings would hold true in other age ranges, such as women 
>35 years old.
Another limitation of the present study is that immuno-
histochemistry is less quantitative than western blotting. 
Performing this analysis using a housekeeping protein as a 
loading control, such as GAPDH or β‑actin, would have been 
useful. Alternatively, ELISA or a gene expression assessment 
of both receptors using RT‑qPCR could have been conducted. 
However, due to ethical restrictions, sufficient tissue for protein 
extraction could not be obtained in order to pursue this further.
As mentioned, synchronization between blastocyst devel-
opment and the acquisition of endometrial receptivity is a 
prerequisite for the success of IVF, a process that appears to 
be dependent on a number of different events at the hormonal 
and cellular levels. In this study, novel evidence of differen-
tial expression and potential involvement of two key steroid 
hormone receptors in this process was provided; namely, in 
women undergoing treatment during an oocyte donation 
program. The present results, combined with those of in silico 
analyses, suggested that the changes in ER and PR expression 
and cellular distribution are crucial events that can impact 
implantation. This should be investigated further in studies with 
a larger population, which should further validate the original 
findings using alternative, more quantitative approaches, and 
further explore changes between D0‑5 in a ‘non‑biased’ way 
through RNAseq or proteomic analysis instead. Expanding 
our knowledge on this field beyond the two steroid hormone 
receptors described herein, would augment our understanding 
of the signalling mechanisms implicated in infertility, and 
potentially provide novel therapeutic targets. It would have 
Table II. Full names of genes studied in silico including 




POSTN Periostin, osteoblast specific factor
RBP4 Retinol binding protein 4, plasma
MMP26 Matrix metallopeptidase 26
WT1 Wilms tumor 1
LRRC17 Leucine rich repeat containing 17
OSR2 Odd‑skipped related transcription factor 2
HABP2 Hyaluronan binding protein 2
HSD17B2 Hydroxysteroid (17‑β) dehydrogenase 2
PTGER3 Prostaglandin E receptor 3 
SOD3 Superoxide dismutase 3, extracellular
PAEP Progestogen‑associated endometrial protein
THBS4 Thrombospondin 4
EFNB2 Ephrin‑B2
TRHR Thyrotropin‑releasing hormone receptor
ECEL1 Endothelin converting enzyme‑like 1
GLI1 GLI family zinc finger 1
MMP7 Matrix metallopeptidase 7
 (matrilysin, uterine)
COL9A1 Collagen type IX, α 1
SERPINA1 Serpin peptidase inhibitor, clade A,
 member 1
CTNNA2 Catenin (cadherin‑associated protein), α 2
KLK3 Kallikrein‑related peptidase 3
JDP2 Jun dimerization protein 2
IGFBP1 Insulin‑like growth factor binding protein 1
KLF9 Kruppel‑like factor 9
C20orf103 Chromosome 20 open reading frame 103
NID2 Nidogen 2 (osteonidogen)
CAPN6 Calpain 6
OVGP1 Oviductal glycoprotein 1, 120kDa
NID1 Nidogen 1
SLC9A3 Solute carrier family 9 (sodium/hydrogen 
 exchanger), member 3
PGR Progesterone receptor
SF1 Splicing factor 1
CLU Clusterin
COL4A6 Collage type IV α 6 chain
RRM2B Ribonucleotide reductase regulatory TP53 
 inducible subunit M2B
TRH Thyrotropin‑releasing hormone
NFIA Nuclear factor I/A
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been useful to investigate the downstream signalling as 
well. However, for this to happen we would need to generate 
primary cell cultures from the biopsies. This was impossible 
due to the small size of the study. There are no commercially 
available cell lines to mimic this pharmacological milieu. We 
mention this under limitations in our discussion. It is for the 
very reason that we embarked on bioinformatic analysis to 
we provide novel evidence for a potential crosstalk of these 
receptors during the implantation window with genes that are 
implicated in RIF and UIF.
In conclusion, successful implantation implies synchroniza-
tion between a blastocyst and the endometrium, which undergoes 
structural and functional remodelling. It was shown herein that 
both ER‑a and PR‑B were expressed abundantly on days 0 and 
5, showing significant variation in the nodal and stromal prepa-
rations. Age appeared to be a critical factor, since ER‑a nodal 
staining showed higher values in the age group of oocyte donors 
<30 years old. Therefore, focusing on the functional charac-
teristics of the endometrium will provide a better insight into 
successful embryo implantation, thus improving IVF results.
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